Education
About Us
Working with TipRanks
Follow Us
BONESUPPORT HOLDING AB (DE:2B4)
FRANKFURT:2B4
2B4 Stock Chart & Stats
€17.08
-€0.24(-0.69%)
At close: 4:00 PM EST
€17.08
-€0.24(-0.69%)
Day’s Range― - ―
52-Week Range€15.50 - €34.22
Previous CloseN/A
Volume165.00
Average Volume (3M)55.00
Market Cap
€1.19B
Enterprise Value€13.07B
Total Cash (Recent Filing)€377.99M
Total Debt (Recent Filing)€15.88M
Price to Earnings (P/E)92.1
Beta0.10
Next Earnings
Apr 22, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding65,859,190
10 Day Avg. Volume69
30 Day Avg. Volume55
Financial Highlights & Ratios
PEG Ratio14.81
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio56.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.44
Revenue Forecast (FY)€140.38M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsBONESUPPORT’s CERAMENT products deliver exceptionally high gross margins, reflecting proprietary product economics and low direct costs. Durable margin advantage supports sustained cash generation, funds clinical/commercial investment, and provides pricing flexibility versus competitors over the next several years.
U.S. Commercial MomentumRapid U.S. adoption and expansion into >140 Level 1 trauma centers shows scalable commercial traction in the largest market. A growing installed base and improving sales per working day create a durable revenue runway as hospital adoption deepens and cross‑selling into trauma, spine and revision arthroplasty progresses.
Conservative Balance Sheet And Cash FlowThe transition to strong operating and free cash flow, combined with very low leverage, gives the company financial flexibility to fund clinical trials, market expansion and absorb regulatory delays. Reliable cash conversion in 2025 improves the durability of growth investments and reduces refinancing risk.
Bears Say
Regulatory Uncertainty For CERAMENT VReclassification to a De Novo pathway materially extends approval timing and introduces execution risk for an antibiotic‑eluting product with high upside. Delayed market entry reduces near‑term revenue contribution and increases the importance of existing products to hit multi‑year targets.
Rising Commercial And Distributor CostsAs the company scales geographically, higher commissions, distributor fees and staffing investments are structurally increasing operating costs. This can compress operating leverage and margins unless adoption and reimbursement gains outpace incremental commercial spend over the medium term.
Historic Profit And Cash VolatilityWhile profitability and cash flow have improved recently, prior years showed volatility and 2025 margin normalization suggests earnings can swing materially. Such volatility complicates forward planning and increases risk that temporary headwinds or one‑off costs could reverse margins or cash conversion.
BONESUPPORT HOLDING AB News
2B4 FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was €15.50 and its highest was €34.22 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is €1.19B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Apr 22, 2026 which is in 48 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Feb 24, 2026. The company reported €0.062 earnings per share for the quarter, missing the consensus estimate of €0.082 by -€0.02.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.09.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of €0.062 in its last earnings report, missing expectations of €0.082. Following the earnings report the stock price went up 7.38%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in DE:2B4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
2B4 Company Deck
2B4 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial picture: strong underlying sales growth (especially CERAMENT G in the U.S.), high gross margins, solid adjusted profitability and cash generation, plus continued geographic and product expansion (spine launch, De Novo path for CERAMENT V). Offsetting risks include currency translation headwinds that depressed reported growth, headwinds in Germany, rising commercial costs and distributor fees, newly introduced U.S. tariffs, and regulatory timing/uncertainty around CERAMENT V. Early-stage adoption in many newly opened accounts is still developing and some segments (spine, revision arthroplasty) require more evidence. Overall, the positives materially outweigh the challenges, with the company signaling confidence in 2026 constant-currency growth guidance (at least ~35%).View all DE:2B4 earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---